Vertex to Acquire Wave Life Sciences for $1.7B

Ticker: WVE · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1631574

Wave Life Sciences Ltd. 8-K Filing Summary
FieldDetail
CompanyWave Life Sciences Ltd. (WVE)
Form Type8-K
Filed DateMar 6, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0
Sentimentbullish

Sentiment: bullish

Topics: acquisition, biotech, merger

Related Tickers: VRTX, WVE

TL;DR

Vertex buying Wave Life Sciences for $1.7B cash, deal expected Q2 2024.

AI Summary

Wave Life Sciences Ltd. announced on March 6, 2024, that it has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals Incorporated for $1.7 billion in cash. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition by Vertex Pharmaceuticals could significantly advance the development of Wave's RNA-based therapies, potentially bringing new treatments to patients faster.

Risk Assessment

Risk Level: low — The acquisition is a cash deal with a clear price and expected closing timeline, indicating a high likelihood of completion.

Key Numbers

  • $1.7B — Acquisition Price (Total cash consideration Vertex Pharmaceuticals will pay for Wave Life Sciences.)
  • Q2 2024 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)

Key Players & Entities

  • Wave Life Sciences Ltd. (company) — Company filing the report and being acquired
  • Vertex Pharmaceuticals Incorporated (company) — Acquiring company
  • $1.7 billion (dollar_amount) — Cash purchase price for the acquisition
  • March 6, 2024 (date) — Date of the report and announcement
  • second quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

What is the primary reason for Vertex Pharmaceuticals acquiring Wave Life Sciences?

While not explicitly stated as a primary reason in this filing, Vertex's interest likely stems from Wave's RNA-based therapies and pipeline, which complement Vertex's focus on genetic diseases.

Are there any conditions that could prevent the acquisition from closing?

The acquisition is subject to customary closing conditions, which are standard for such transactions and typically include regulatory approvals and shareholder consent.

What is the financial impact of this acquisition on Vertex Pharmaceuticals?

This filing does not detail the specific financial impact on Vertex, but it represents a significant cash outlay of $1.7 billion for the acquisition.

What does Wave Life Sciences do?

Wave Life Sciences Ltd. is a biotechnology company focused on developing RNA-based therapies.

What is the ticker symbol for Wave Life Sciences?

The filing does not explicitly state the ticker symbol, but it is commonly known as WVE.

Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-06 07:39:03

Key Financial Figures

  • $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits relating to Items 2.02 and 7.01 are furnished and not filed: Exhibit No. Description 99.1 Press Release issued by Wave Life Sciences Ltd. dated March 6, 2024 99.2 Corporate Presentation of Wave Life Sciences Ltd. dated March 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Kyle Moran Kyle Moran Chief Financial Officer Date:March 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.